Labcorp Exceeds Q1 Expectations, Boosts Full-Year Revenue & EPS Guidance on Strong Performance

summarizeSummary

Labcorp reported strong first-quarter results, exceeding revenue and EPS expectations, and subsequently raised its full-year 2026 guidance for both revenue and adjusted EPS.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Labcorp reported Q1 2026 revenue of $3.54 billion, up 5.8% year-over-year, and adjusted diluted EPS of $4.25, an increase of 10.6% from Q1 2025. Diluted EPS rose 32.8% to $3.35.

• Full-Year 2026 Guidance Raised

  The company raised its full-year 2026 enterprise revenue guidance to a range of $14.65 billion to $14.80 billion (up 20 basis points at the midpoint) and adjusted EPS guidance to $17.70 to $18.35 (up 13 cents at the midpoint).

• Strategic Growth Initiatives

  Labcorp advanced its leadership in specialty and companion diagnostics, expanded collaborations with health systems, and invested in technology and AI to enhance patient and provider experience.

• Continued Capital Allocation

  In Q1 2026, Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million of common stock, and paid $61.2 million in dividends, demonstrating a disciplined approach to capital management.

auto_awesomeAnalysis

Labcorp's first-quarter results demonstrate robust operational performance, with both revenue and adjusted EPS surpassing prior year figures and market estimates. The decision to raise full-year guidance for both revenue and adjusted EPS signals strong management confidence in continued growth and profitability. This positive outlook is supported by strategic advancements in specialty diagnostics, health system collaborations, and technology investments, which are expected to drive future performance. The ongoing share repurchase program also indicates a commitment to returning capital to shareholders.